# Drug Discovery Pipeline: Complete Integration Guide

This guide demonstrates how the upgraded **Literature Agent v2.0** integrates with all downstream agents (Hypothesis, Experiment, Analysis, Report) for end-to-end drug discovery automation.

## 🧬 Complete Drug Discovery Workflow

```
┌─────────────────────────────────────────────────────────────┐
│           DRUG DISCOVERY RESEARCH QUESTION                  │
│  "How can we discover new PD-1 checkpoint inhibitors for    │
│   improving cancer immunotherapy response rates?"           │
└────────────────┬────────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────────────────────────┐
│  📚 PHASE 1: BIOMEDICAL LITERATURE DISCOVERY               │
│  (Europe PMC + PubChem Integration)                        │
├─────────────────────────────────────────────────────────────┤
│                                                              │
│  ✓ Search biomedical literature (Europe PMC)               │
│  ✓ Extract chemical compounds (PubChem)                    │
│  ✓ Identify disease targets from MeSH terms                │
│  ✓ Map molecular targets (proteins, genes)                 │
│  ✓ Extract assay types and bioactivity data                │
│  ✓ Identify research gaps in:                              │
│    - Untested compounds                                    │
│    - Unexplored drug targets                               │
│    - Limited bioactivity data                              │
│    - Novel mechanisms of action                            │
│                                                              │
│  OUTPUTS:                                                    │
│  • Papers: [BiomedicalRecord] with biomedical attrs       │
│  • disease_targets: ["PD-1", "CTLA-4", ...]               │
│  • molecular_targets: ["CD28", "TCR", ...]                │
│  • assay_types: ["ELISA", "cell viability", ...]          │
│  • compound_cids: ["1234567", "2345678", ...]             │
│  • mesh_terms: ["Immunotherapy", "Neoplasms", ...]        │
│  • gaps: [ResearchGap] with drug discovery focus          │
│                                                              │
└────────────────┬────────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────────────────────────┐
│  💡 PHASE 2: HYPOTHESIS GENERATION (Enhanced)              │
│  (Uses biomedical attributes from Literature Agent)        │
├─────────────────────────────────────────────────────────────┤
│                                                              │
│  INPUT from Literature Agent:                              │
│  • Disease targets: PD-1, CTLA-4, LAG-3                    │
│  • Molecular targets: CD28, TCR signaling                  │
│  • Suggested assay types: kinase assay, cell viability    │
│  • Compound info: molecular weight, structure              │
│  • Research gaps: novel target combinations                │
│                                                              │
│  Hypothesis Generation Strategies:                         │
│  1. Gap-bridging:                                          │
│     "Combination of PD-1 + CTLA-4 inhibitors would        │
│      synergize immune checkpoint blockade"                 │
│                                                              │
│  2. Trend detection:                                       │
│     "Emerging non-PD-1 targets show promise in            │
│      resistant cancers based on recent publications"      │
│                                                              │
│  3. Cross-domain synthesis:                                │
│     "Scaffold hopping from identified hits to new          │
│      chemical series with improved properties"             │
│                                                              │
│  4. Novel combination:                                     │
│     "Combine checkpoint inhibitor with VEGF inhibitor      │
│      to overcome resistance"                               │
│                                                              │
│  5. Contradiction resolution:                              │
│     "Some studies show off-target effects; hypothesis:     │
│      target-selective variants eliminate toxicity"        │
│                                                              │
│  OUTPUTS:                                                    │
│  • Hypothesis 1: {                                         │
│      title: "Novel PD-1/CTLA-4 dual inhibitor",          │
│      tested_variables: [                                  │
│        "compound_series": "quinolone scaffold",           │
│        "molecular_targets": ["PD-1", "CTLA-4"],           │
│        "assay_types": ["kinase", "cell viability"]        │
│      ],                                                    │
│      predictions: "Synergistic immune activation",        │
│      novelty: 0.82,                                       │
│      feasibility: 0.78,                                   │
│      impact: 0.91,                                        │
│      overall_score: 0.83                                  │
│    }                                                       │
│  • Hypothesis 2-5: Similar structure                       │
│                                                              │
│  • All ranked by overall_score                             │
│                                                              │
└────────────────┬────────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────────────────────────┐
│  🧪 PHASE 3: EXPERIMENT DESIGN (Drug Discovery Context)   │
│  (Uses molecular targets and assay types)                  │
├─────────────────────────────────────────────────────────────┤
│                                                              │
│  Selected Hypothesis:                                      │
│  "Novel PD-1/CTLA-4 dual inhibitor compound series"       │
│                                                              │
│  Experiment Design Outputs:                                │
│  • experiment_type: "High-Throughput Screening + SAR"     │
│  • sample_size: 500 (compounds in series)                 │
│  • assay_plan: {                                          │
│      primary: "PD-1 kinase assay (TR-FRET)",             │
│      secondary: [                                         │
│        "CTLA-4 binding assay",                           │
│        "Off-target selectivity panel (100 targets)"      │
│      ],                                                   │
│      cellular: "Jurkat T cell activation assay"          │
│    }                                                      │
│  • budget_estimate: $125,000                              │
│  • timeline: 16 weeks                                     │
│  • datasets_needed: [                                     │
│      "PubChem bioactivity data",                         │
│      "Internal compound library",                        │
│      "Target protein structures"                         │
│    ]                                                     │
│  • success_probability: 0.68                              │
│                                                              │
│  RISK ASSESSMENT:                                          │
│  • Off-target toxicity (mechanism validation needed)      │
│  • Limited solubility compounds (ADME optimization)       │
│  • Species differences in immunogenicity                  │
│                                                              │
│  MITIGATION STRATEGIES:                                    │
│  • Expanded selectivity panel (> 100 kinases)             │
│  • ADME profiling early in discovery                      │
│  • Humanized assay systems                                │
│                                                              │
│  👤 HUMAN APPROVAL REQUIRED before execution               │
│                                                              │
└────────────────┬────────────────────────────────────────────┘
                 ↓
       [AWAITING HUMAN APPROVAL]
                 ↓
        [✅ APPROVED] → Continue
                 ↓
┌─────────────────────────────────────────────────────────────┐
│  📊 PHASE 4: RESULTS ANALYSIS                              │
│  (Simulated or real experimental results)                  │
├─────────────────────────────────────────────────────────────┤
│                                                              │
│  Simulated Results (for demo):                             │
│  • Total compounds screened: 500                           │
│  • Hits identified (>50% inhibition): 45                   │
│  • Lead compounds (>70% inhibition): 12                    │
│  • Selectivity maintained (>100-fold): 8                   │
│  • Solubility adequate (>10 µM): 6                        │
│                                                              │
│  Statistical Analysis:                                     │
│  • Primary finding: Dual inhibitor showed 2.3x better     │
│    immune T cell activation than PD-1 alone (p < 0.001)   │
│  • Effect size: Cohen's d = 0.78 (medium effect)          │
│  • Confidence interval: [1.8x, 2.8x]                      │
│                                                              │
│  Hypothesis Interpretation:                                │
│  ✓ CONFIRMED: Dual target approach shows promise          │
│  ✓ Novel compounds identified with desired properties     │
│  ✓ Effect size clinically meaningful                      │
│                                                              │
│  Secondary Findings:                                       │
│  • Scaffold optimization improved selectivity             │
│  • Solubility correlates with cell permeability           │
│  • Species cross-reactivity demonstrated                  │
│                                                              │
│  Implications:                                             │
│  1. Lead compounds warrant preclinical development        │
│  2. ADME optimization should prioritize solubility        │
│  3. Animal PK studies recommended next step               │
│                                                              │
│  FINDINGS SUMMARY:                                         │
│  • Finding 1: Dual inhibition > single target (p<0.001)   │
│  • Finding 2: 6 leads with drug-like properties           │
│  • Finding 3: Selectivity maintained across 100+ targets  │
│  • Finding 4: Cell permeability correlates with activity  │
│                                                              │
│  Feedback Loop Trigger: Hypothesis CONFIRMED - Continue   │
│                                                              │
└────────────────┬────────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────────────────────────┐
│  📝 PHASE 5: PUBLICATION-READY REPORT GENERATION          │
│  (Includes biomedical literature + findings)              │
├─────────────────────────────────────────────────────────────┤
│                                                              │
│  Generated Research Paper:                                 │
│                                                              │
│  ┌─ ABSTRACT ────────────────────────────────────────────┐ │
│  │ Background: PD-1/CTLA-4 combinations show clinical   │ │
│  │ promise. We sought to identify novel dual inhibitors │ │
│  │ with improved selectivity.                           │ │
│  │                                                       │ │
│  │ Methods: High-throughput screening of 500 compounds   │ │
│  │ in quinolone and indazole scaffolds...               │ │
│  │                                                       │ │
│  │ Results: Dual inhibitor series (n=45 hits) showed   │ │
│  │ 2.3-fold improved immune activation vs PD-1 alone    │ │
│  │ (p < 0.001). Six leads demonstrated drug-like        │ │
│  │ properties with >100-fold selectivity.               │ │
│  │                                                       │ │
│  │ Conclusions: Novel dual checkpoint inhibitors show   │ │
│  │ promise for improved immunotherapy efficacy...       │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  ┌─ INTRODUCTION ─────────────────────────────────────────┐ │
│  │ Section 1: Background on cancer immunotherapy        │ │
│  │   - Cites 25+ papers from Europe PMC search          │ │
│  │   - Establishes clinical need                        │ │
│  │                                                       │ │
│  │ Section 2: Checkpoint inhibitor mechanism            │ │
│  │   - PD-1, CTLA-4, LAG-3 pathways                     │ │
│  │   - Synergistic combination rationale                │ │
│  │                                                       │ │
│  │ Section 3: Existing approaches & gaps                │ │
│  │   - Lists drug candidates from PubChem              │ │
│  │   - Identifies selectivity and ADME issues          │ │
│  │   - Cites research gaps from Literature Agent       │ │
│  │                                                       │ │
│  │ Section 4: Research hypothesis                       │ │
│  │   - Dual inhibitor rationale                         │ │
│  │   - Novelty of approach                              │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  ┌─ METHODOLOGY ──────────────────────────────────────────┐ │
│  │ • Compound selection from chemical libraries          │ │
│  │ • High-throughput kinase assay protocol               │ │
│  │ • Off-target selectivity testing (100+ kinases)       │ │
│  │ • Cellular potency: T cell activation assay          │ │
│  │ • ADME: Solubility, permeability, stability          │ │
│  │ • Statistical analysis methods                        │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  ┌─ RESULTS ──────────────────────────────────────────────┐ │
│  │ • Screening outcomes: 500 compounds → 45 hits        │ │
│  │ • Lead identification: 6 compounds with profile       │ │
│  │ • Potency data: IC50 values, selectivity ratios       │ │
│  │ • Cell-based results: 2.3x better activation         │ │
│  │ • Structure-activity relationships (SAR)             │ │
│  │ • ADME properties: Solubility, Caco-2 data           │ │
│  │ • Figure 1: Compound structures & potencies          │ │
│  │ • Figure 2: Dose-response curves                     │ │
│  │ • Table 1: Hit summary & properties                  │ │
│  │ • Table 2: SAR summary for optimization              │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  ┌─ DISCUSSION ───────────────────────────────────────────┐ │
│  │ • Comparison with published compounds                 │ │
│  │ • Mechanism of dual target synergy                    │ │
│  │ • SAR insights for next-generation design            │ │
│  │ • Species cross-reactivity implications              │ │
│  │ • Limitations: In vitro only, specific scaffold      │ │
│  │ • Future directions: In vivo efficacy, tolerability  │ │
│  │ • Broader implications for immunotherapy             │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  ┌─ REFERENCES ───────────────────────────────────────────┐ │
│  │ • 65 citations in APA format                          │ │
│  │ • 40+ from Europe PMC biomedical literature          │ │
│  │ • 15+ from PubChem compound data                      │ │
│  │ • 10+ recent reviews on immunotherapy                │ │
│  │ • All with DOI and PubMed links                       │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  ┌─ SUPPLEMENTARY MATERIALS ──────────────────────────────┐ │
│  │ • Raw screening data (all 500 compounds)              │ │
│  │ • Compound structures (mol/SDF files)                 │ │
│  │ • Detailed assay protocols                            │ │
│  │ • Extended dose-response curves                       │ │
│  │ • SAR analysis tables                                 │ │
│  │ • Animal study protocols (for follow-up)             │ │
│  └───────────────────────────────────────────────────────┘ │
│                                                              │
│  KNOWLEDGE GRAPH EXPORT:                                   │
│  • Entities: 150+ (compounds, targets, diseases)         │ │
│  • Relationships: Tested_by, Inhibits, Treats           │ │
│  • Properties: potency, selectivity, ADME               │ │
│  • Formats: RDF/XML, Turtle, JSON-LD                    │ │
│                                                              │
│  PAPER STATISTICS:                                         │
│  • Word count: 8,500                                      │ │
│  • Pages: 12-15 (journal format)                          │ │
│  • Figures: 6                                             │ │
│  • Tables: 4                                              │ │
│  • References: 65                                         │ │
│  • Supplementary files: 8                                 │ │
│                                                              │
│  OUTPUT FORMATS:                                           │ │
│  • Markdown: ./results/research_paper.md                  │ │
│  • HTML: ./results/research_paper.html (interactive)      │ │
│  • PDF: ./results/research_paper.pdf (publication-ready)  │ │
│  • JSON: ./results/research_paper.json (structured)       │ │
│  • BibTeX: ./results/citations.bib (reference manager)    │ │
│  • Knowledge Graph: ./results/knowledge_graph.json        │ │
│                                                              │
│  ✅ PUBLICATION READY                                     │ │
│                                                              │
└────────────────┬────────────────────────────────────────────┘
                 ↓
            [COMPLETE]
                 
✨ RESEARCH PAPER READY FOR JOURNAL SUBMISSION
    OR HACKATHON COMPETITION
```

## 🔄 Data Flow Between Agents

### Literature → Hypothesis

```python
# Literature Agent outputs
{
  "papers": [
    {
      "title": "PD-1 checkpoint blockade in cancer...",
      "abstract": "...",
      "disease_targets": ["PD-1", "CTLA-4"],
      "molecular_targets": ["CD28", "TCR"],
      "assay_types": ["kinase assay", "ELISA"],
      "mesh_terms": ["Immunotherapy", "Neoplasms"],
      "compound_cids": ["1234567", "2345678"],
      "pmcid": "PMC1234567"
    }
  ],
  "gaps": [
    {
      "gap_description": "Limited data on dual target synergy",
      "related_papers": [...],
      "priority_level": "high",
      "confidence": 0.85
    }
  ]
}

# Hypothesis Agent uses these for generation:
# - Disease targets → what to target
# - Molecular targets → mechanism of action
# - Assay types → how to test
# - Gaps → novel hypotheses
```

### Hypothesis → Experiment

```python
# Hypothesis Agent outputs
{
  "title": "Dual PD-1/CTLA-4 inhibitor compound series",
  "molecular_targets": ["PD-1", "CTLA-4"],
  "assay_types": ["kinase", "cell viability"],
  "suggested_experiments": ["HTS", "SAR"],
  "novelty": 0.82,
  "feasibility": 0.78
}

# Experiment Agent uses this to:
# - Select assay types → design protocol
# - Identify targets → model selection
# - Assess feasibility → resource estimation
```

### Experiment → Analysis

```python
# Experiment Agent outputs
{
  "experiment_type": "High-Throughput Screening",
  "sample_size": 500,
  "assay_types": ["PD-1 kinase", "CTLA-4 kinase", "selectivity"],
  "budget": 125000,
  "success_probability": 0.68
}

# Analysis Agent uses this to:
# - Validate results vs experiment type
# - Interpret findings in experiment context
# - Calculate effect sizes
```

### Analysis → Report

```python
# Analysis Agent outputs
{
  "hypothesis_confirmed": true,
  "primary_finding": {
    "description": "Dual inhibition superior to single target",
    "effect_size": 0.78,
    "p_value": 0.0001,
    "confidence_level": 0.95
  },
  "findings": [
    {
      "name": "Hit rate",
      "value": 9.0,
      "unit": "percent"
    }
  ]
}

# Report Agent uses this to:
# - Structure results section
# - Write findings in scientific context
# - Generate discussion
# - Create knowledge graph
```

## 💾 Data Structures Through Pipeline

### BiomedicalRecord (Literature Agent output)

```python
@dataclass
class BiomedicalRecord:
    # Core fields
    title: str
    authors: list[str]
    publication_year: int
    abstract: str
    
    # Biomedical attributes
    pmcid: str
    mesh_terms: list[str]
    disease_targets: list[str]
    molecular_targets: list[str]
    compound_cids: list[str]
    assay_types: list[str]
    organism_studied: str
```

### Hypothesis (Hypothesis Agent output)

```python
@dataclass
class Hypothesis:
    title: str
    molecular_targets: list[str]
    disease_context: str
    tested_variables: dict
    predictions: list[str]
    novelty: float
    feasibility: float
    impact: float
    overall_score: float
```

### ExperimentalDesign (Experiment Agent output)

```python
@dataclass
class ExperimentalDesign:
    experiment_type: str
    sample_size: int
    assay_plan: dict
    total_cost: float
    duration_weeks: int
    success_prediction: dict
```

## 🎯 Key Integration Points

### 1. Disease Target Continuity
- **Literature**: Extracts disease_targets from literature
- **Hypothesis**: Uses targets to formulate hypotheses
- **Experiment**: Designs assays against these targets
- **Analysis**: Interprets results for these targets
- **Report**: Discusses findings in disease context

### 2. Molecular Target Mapping
- **Literature**: Identifies protein/gene targets
- **Hypothesis**: Proposes target interactions
- **Experiment**: Tests target engagement
- **Analysis**: Validates target mechanism
- **Report**: Describes mechanism in paper

### 3. Assay Type Specification
- **Literature**: Extracts assay types from papers
- **Hypothesis**: Suggests appropriate assays
- **Experiment**: Designs detailed protocols
- **Analysis**: Interprets assay results
- **Report**: Describes methods used

### 4. Compound Information
- **Literature**: Retrieves PubChem compound data
- **Hypothesis**: Identifies lead structures
- **Experiment**: Tests compound series
- **Analysis**: Analyzes SAR and properties
- **Report**: Describes chemistry and optimization

## 🧬 Drug Discovery Specific Features

### Biomedical Entity Recognition
The pipeline automatically recognizes:
- Disease names (Cancer, Alzheimer's, COVID-19)
- Drug names (Aspirin, Metformin, PD-1 inhibitors)
- Protein targets (EGFR, TP53, BRCA1)
- Genes and pathways
- Cell types and organisms
- Assay methods and techniques

### MeSH Term Filtering
MeSH terms enable:
- Precise disease area filtering
- Method identification
- Organ system targeting
- Population characteristics

### PubChem Bioactivity Integration
Compounds include:
- Molecular properties (weight, formula, SMILES)
- Bioactivity data (IC50s, Ki values)
- Target information
- Assay types used
- Organism tested

## 📊 Complete Example Output

See `examples_drug_discovery.py` for runnable examples:
1. Cancer drug discovery search
2. Compound screening
3. Drug resistance gap analysis
4. Target validation
5. ADME property optimization
6. Combination therapy research
7. Clinical translation gaps

## 🚀 Running the Complete Pipeline

```python
import asyncio
from run_discovery_loop import DiscoveryOrchestrator

async def main():
    orchestrator = DiscoveryOrchestrator()
    
    state = await orchestrator.run_discovery_loop(
        research_question="What are novel PD-1/CTLA-4 dual inhibitors for cancer?",
        literature_limit=100,
        auto_approve=False
    )
    
    return state

# Results saved to ./results/
# - workflow_state_TIMESTAMP.json
# - research_paper_TIMESTAMP.md
# - knowledge_graph_TIMESTAMP.json
```

## 📈 Metrics Tracked

The complete pipeline tracks:
- **Literature Phase**: Papers found, gaps identified, MeSH terms extracted
- **Hypothesis Phase**: Hypotheses generated, scores calculated, rankings
- **Experiment Phase**: Design type, budget, success probability
- **Analysis Phase**: Effect sizes, p-values, hypothesis confirmation
- **Report Phase**: Paper sections, citations, figures, tables
- **Overall**: Execution time, feedback loops, quality checks

## 🔗 Related Documentation

- `agents/literature_agent/DRUG_DISCOVERY_GUIDE.md` - Literature Agent API
- `agents/hypothesis_agent/README.md` - Hypothesis generation strategies
- `agents/experiment_agent/PHASE3_SUMMARY.md` - Experiment design details
- `agents/analysis_agent/PHASE4_SUMMARY.md` - Statistical analysis methods
- `agents/report_agent/PHASE5_SUMMARY.md` - Report generation features
- `ORCHESTRATOR_README.md` - Master orchestrator documentation

---

**Ready for drug discovery research automation!** 🧬
